Cargando…

Inhibition of experimental autoimmune encephalomyelitis by tolerance-promoting DNA vaccination focused to dendritic cells

In this study we analysed the effects of prophylactic biolistic DNA vaccination with plasmids encoding the encephalitogenic protein myelin oligodendrocyte glycoprotein (MOG) on the severity of a subsequently MOGp35-55-induced EAE and on the underlying immune response. We compared the outcome of vacc...

Descripción completa

Detalles Bibliográficos
Autores principales: Castor, Timo, Yogev, Nir, Blank, Thomas, Barwig, Christina, Prinz, Marco, Waisman, Ari, Bros, Matthias, Reske-Kunz, Angelika B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800700/
https://www.ncbi.nlm.nih.gov/pubmed/29408931
http://dx.doi.org/10.1371/journal.pone.0191927
_version_ 1783298251934400512
author Castor, Timo
Yogev, Nir
Blank, Thomas
Barwig, Christina
Prinz, Marco
Waisman, Ari
Bros, Matthias
Reske-Kunz, Angelika B.
author_facet Castor, Timo
Yogev, Nir
Blank, Thomas
Barwig, Christina
Prinz, Marco
Waisman, Ari
Bros, Matthias
Reske-Kunz, Angelika B.
author_sort Castor, Timo
collection PubMed
description In this study we analysed the effects of prophylactic biolistic DNA vaccination with plasmids encoding the encephalitogenic protein myelin oligodendrocyte glycoprotein (MOG) on the severity of a subsequently MOGp35-55-induced EAE and on the underlying immune response. We compared the outcome of vaccination with MOG-encoding plasmids alone or in combination with vectors encoding the regulatory cytokines IL-10 and TGF-ß1, respectively. MOG expression was restricted to skin dendritic cells (DCs) by the use of the DC-specific promoter of the fascin1 gene (pFscn-MOG). For comparison, the strong and ubiquitously active CMV promoter was employed (pCMV-MOG), which allows MOG expression in all transfected cells. Expression of IL-10 and TGF-ß1 was controlled by the CMV promoter to yield maximal synthesis (pCMV-IL10, pCMV-TGFß). Co-application of pFscn-MOG and pCMV-IL10 significantly ameliorated EAE pathology, while vaccination with pCMV-MOG plus pCMV-IL10 did not affect EAE outcome. In contrast, vaccination with either of the two MOG-encoding plasmids in combination with pCMV-TGFß significantly attenuated the clinical EAE symptoms. Mechanistically, we observed diminished infiltration of Th17 and Th1 cells as well as macrophages/DCs into the CNS, which correlated with decreased MOGp35-55-specific production of IL-17 and IFN-ϫ by spleen cells and reduced peptide-specific T cell proliferation. Our findings suggest deletion of or anergy induction in MOG-specific CD4(+) T cells by the suppressive vaccination platform employed. MOG expression driven by the DC-specific fascin1 promoter yielded similar inhibitory effects on EAE progression as the ubiquitously active viral CMV promoter, when coapplying pCMV-TGFß. Our finding that pCMV-IL10 promoted tolerogenic effects only, when coapplied with pFscn-MOG, but not pCMV-MOG suggests that IL-10 affected only directly transfected DCs (pFscn-MOG), but not neighbouring DCs that engulfed MOG-containing vesicles derived from transfected keratinocytes (pCMV-MOG). Thus, due to its DC-restricted expression, the fascin1 promoter might be an interesting alternative to ubiquitously expressed promoters for vaccination strategies.
format Online
Article
Text
id pubmed-5800700
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-58007002018-02-23 Inhibition of experimental autoimmune encephalomyelitis by tolerance-promoting DNA vaccination focused to dendritic cells Castor, Timo Yogev, Nir Blank, Thomas Barwig, Christina Prinz, Marco Waisman, Ari Bros, Matthias Reske-Kunz, Angelika B. PLoS One Research Article In this study we analysed the effects of prophylactic biolistic DNA vaccination with plasmids encoding the encephalitogenic protein myelin oligodendrocyte glycoprotein (MOG) on the severity of a subsequently MOGp35-55-induced EAE and on the underlying immune response. We compared the outcome of vaccination with MOG-encoding plasmids alone or in combination with vectors encoding the regulatory cytokines IL-10 and TGF-ß1, respectively. MOG expression was restricted to skin dendritic cells (DCs) by the use of the DC-specific promoter of the fascin1 gene (pFscn-MOG). For comparison, the strong and ubiquitously active CMV promoter was employed (pCMV-MOG), which allows MOG expression in all transfected cells. Expression of IL-10 and TGF-ß1 was controlled by the CMV promoter to yield maximal synthesis (pCMV-IL10, pCMV-TGFß). Co-application of pFscn-MOG and pCMV-IL10 significantly ameliorated EAE pathology, while vaccination with pCMV-MOG plus pCMV-IL10 did not affect EAE outcome. In contrast, vaccination with either of the two MOG-encoding plasmids in combination with pCMV-TGFß significantly attenuated the clinical EAE symptoms. Mechanistically, we observed diminished infiltration of Th17 and Th1 cells as well as macrophages/DCs into the CNS, which correlated with decreased MOGp35-55-specific production of IL-17 and IFN-ϫ by spleen cells and reduced peptide-specific T cell proliferation. Our findings suggest deletion of or anergy induction in MOG-specific CD4(+) T cells by the suppressive vaccination platform employed. MOG expression driven by the DC-specific fascin1 promoter yielded similar inhibitory effects on EAE progression as the ubiquitously active viral CMV promoter, when coapplying pCMV-TGFß. Our finding that pCMV-IL10 promoted tolerogenic effects only, when coapplied with pFscn-MOG, but not pCMV-MOG suggests that IL-10 affected only directly transfected DCs (pFscn-MOG), but not neighbouring DCs that engulfed MOG-containing vesicles derived from transfected keratinocytes (pCMV-MOG). Thus, due to its DC-restricted expression, the fascin1 promoter might be an interesting alternative to ubiquitously expressed promoters for vaccination strategies. Public Library of Science 2018-02-06 /pmc/articles/PMC5800700/ /pubmed/29408931 http://dx.doi.org/10.1371/journal.pone.0191927 Text en © 2018 Castor et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Castor, Timo
Yogev, Nir
Blank, Thomas
Barwig, Christina
Prinz, Marco
Waisman, Ari
Bros, Matthias
Reske-Kunz, Angelika B.
Inhibition of experimental autoimmune encephalomyelitis by tolerance-promoting DNA vaccination focused to dendritic cells
title Inhibition of experimental autoimmune encephalomyelitis by tolerance-promoting DNA vaccination focused to dendritic cells
title_full Inhibition of experimental autoimmune encephalomyelitis by tolerance-promoting DNA vaccination focused to dendritic cells
title_fullStr Inhibition of experimental autoimmune encephalomyelitis by tolerance-promoting DNA vaccination focused to dendritic cells
title_full_unstemmed Inhibition of experimental autoimmune encephalomyelitis by tolerance-promoting DNA vaccination focused to dendritic cells
title_short Inhibition of experimental autoimmune encephalomyelitis by tolerance-promoting DNA vaccination focused to dendritic cells
title_sort inhibition of experimental autoimmune encephalomyelitis by tolerance-promoting dna vaccination focused to dendritic cells
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800700/
https://www.ncbi.nlm.nih.gov/pubmed/29408931
http://dx.doi.org/10.1371/journal.pone.0191927
work_keys_str_mv AT castortimo inhibitionofexperimentalautoimmuneencephalomyelitisbytolerancepromotingdnavaccinationfocusedtodendriticcells
AT yogevnir inhibitionofexperimentalautoimmuneencephalomyelitisbytolerancepromotingdnavaccinationfocusedtodendriticcells
AT blankthomas inhibitionofexperimentalautoimmuneencephalomyelitisbytolerancepromotingdnavaccinationfocusedtodendriticcells
AT barwigchristina inhibitionofexperimentalautoimmuneencephalomyelitisbytolerancepromotingdnavaccinationfocusedtodendriticcells
AT prinzmarco inhibitionofexperimentalautoimmuneencephalomyelitisbytolerancepromotingdnavaccinationfocusedtodendriticcells
AT waismanari inhibitionofexperimentalautoimmuneencephalomyelitisbytolerancepromotingdnavaccinationfocusedtodendriticcells
AT brosmatthias inhibitionofexperimentalautoimmuneencephalomyelitisbytolerancepromotingdnavaccinationfocusedtodendriticcells
AT reskekunzangelikab inhibitionofexperimentalautoimmuneencephalomyelitisbytolerancepromotingdnavaccinationfocusedtodendriticcells